DAPT
DAPT
DAPT
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4514-5MG | DAPT | 5mg | $116.00 | |
| GBM-4514-25MG | DAPT | 25mg | $399.00 |
-
Description
g-secretase inhibitor
-
Specifications
Bioassays Specification Bio-Activity g-secretase inhibitor Chemical Name N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester Function / Pharmacology Inhibitor of γ-secretase (IC50 in human primary neurons = 115 nM for total Aβ or 200 nM for Aβ42 specifically)1. Oral administration of DAPT has been shown to reduce levels of Aβ in brain extract, cerebrospinal fluid and plasma from mice and rats.2,3 DAPT blocks Notch signaling which promotes neuronal differentiation of precur-sor cells.4 Enhances iPS cells without oncogenes KLF4 and CMYC5. Cell permeable. CAS# 208255-80-5 MW 432.5 Molecular Formula C23H26F2N2O4 Solubility Soluble in DMSO (up to 30 mg/ml). Supplied powder Storage as supplied -20°C Ship temp Ambient References 1) Dovey et al. (2001), Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain; J. Neurochem. 76 173 2) Portelius et al. (2009), Effects of γ-secretase inhibition on the amyloid β isoform pattern in a mouse model of Alzheimer’s disease; Cell Signal. 5 615 3) El Moueddon et al. (2006), Reduction of Aβ levels in the Sprague Dawley rat after oral administration of the functional γ-secretase inhibitor, DAPT: a novel non-transgenic model for Aβ production inhibitors; Curr. Pharma. Des. 12 1671 4) De Smedt et al. (2005), Different thresholds of notch signaling bias human precursor cells towards B-, NK-, monocytic/dendritic, or T-cell lineage in thymus microenvironment; Blood, 106 2236 5) Ichida et al. (2014), Notch inhibition allows oncogene-independent generation of iPS cells; Nature Chem. Biol. 10 632 Antibody Specification Alternate Names LY-374973 Protein Specification Purity >98% - Reviews
| Bioassays Specification | |
| Bio-Activity | g-secretase inhibitor |
| Chemical Name | N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester |
| Function / Pharmacology | Inhibitor of γ-secretase (IC50 in human primary neurons = 115 nM for total Aβ or 200 nM for Aβ42 specifically)1. Oral administration of DAPT has been shown to reduce levels of Aβ in brain extract, cerebrospinal fluid and plasma from mice and rats.2,3 DAPT blocks Notch signaling which promotes neuronal differentiation of precur-sor cells.4 Enhances iPS cells without oncogenes KLF4 and CMYC5. Cell permeable. |
| CAS# | 208255-80-5 |
| MW | 432.5 |
| Molecular Formula | C23H26F2N2O4 |
| Solubility | Soluble in DMSO (up to 30 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Dovey et al. (2001), Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain; J. Neurochem. 76 173 2) Portelius et al. (2009), Effects of γ-secretase inhibition on the amyloid β isoform pattern in a mouse model of Alzheimer’s disease; Cell Signal. 5 615 3) El Moueddon et al. (2006), Reduction of Aβ levels in the Sprague Dawley rat after oral administration of the functional γ-secretase inhibitor, DAPT: a novel non-transgenic model for Aβ production inhibitors; Curr. Pharma. Des. 12 1671 4) De Smedt et al. (2005), Different thresholds of notch signaling bias human precursor cells towards B-, NK-, monocytic/dendritic, or T-cell lineage in thymus microenvironment; Blood, 106 2236 5) Ichida et al. (2014), Notch inhibition allows oncogene-independent generation of iPS cells; Nature Chem. Biol. 10 632 |
| Antibody Specification | |
| Alternate Names | LY-374973 |
| Protein Specification | |
| Purity | >98% |